PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.409
https://www.valueinhealthjournal.com/article/S1098-3015(19)32787-1/fulltext
Title :
PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32787-1&doi=10.1016/j.jval.2019.09.409
First page :
Section Title :
Open access? :
No
Section Order :
10340